Clinical trial
AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer
NCT00245063 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00245063 |
|---|---|
| Title | AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer |
| Official title | Phase II Study of AZD2171 in Patients With Recurrent Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Non-small Cell Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | cediranib maleate, laboratory biomarker analysis, pharmacogenomic studies |
| Enrollment | 25 |
| Start date | Mar 1, 2006 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Oct 27, 2005 |
| Last update posted | Oct 2, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: